Daxor Corporation (NASDAQ:DXR) Sees Large Growth in Short Interest

Daxor Corporation (NASDAQ:DXR) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totaling 6,959 shares, a growth of 198.5% from the September 15th total of 2,331 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 38,746 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research note on Monday, September 21st. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Daxor currently has an average rating of “Moderate Buy”.

Institutional Trading of Daxor

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Crescent Grove Advisors LLC bought a new position in shares of Daxor in the 1st quarter worth $104,000. Susquehanna International Group LLP lifted its stake in shares of Daxor by 97.7% during the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock worth $275,000 after purchasing an additional 13,411 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Daxor during the 1st quarter worth $245,000. Finally, Aristides Capital LLC bought a new stake in Daxor during the first quarter valued at about $403,000. Institutional investors own 1.34% of the company’s stock.

Daxor Price Performance

Shares of DXR stock opened at $10.35 on Wednesday. The company’s 50 day moving average is $10.59 and its 200 day moving average is $10.38. Daxor has a 52-week low of $8.56 and a 52-week high of $14.76.

About Daxor

Daxor Corporation (NASDAQ: DXR) is a medical device company focused on blood-volume measurement and related diagnostic technologies. Its principal product is the BVA-100 Blood Volume Analyzer, which uses an analysis of a blood sample containing a tracer to measure a patient’s total blood volume, plasma volume and red blood cell volume.

The company’s technology is designed to help clinicians assess fluid status and guide treatment decisions in settings such as heart failure, critical care, surgery, trauma and dialysis.